Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Dosage Forms × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Lymphoid 4 Gastrointestinal 4 Genitourinary 3 Other solid neoplasm 2 Thoracic 1 Plasma cell 1 Other 1 Myeloid 1 Endocrine 1 CNS 1 Breast 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 872 Bortezomib 474 Lenalidomide 464 Cyclophosphamide 366 Melphalan 273 Calcium Dobesilate 263 daratumumab 238 pomalidomide 210 carfilzomib 186 fludarabine phosphate 140 fludarabine 137 Thalidomide 125 Peripheral Blood Stem Cell Transplantation 120 Filgrastim 115 ixazomib 94 Mycophenolic Acid 91 Granulocyte Colony-Stimulating Factor 90 Busulfan 89 Whole-Body Irradiation 88 dexamethasone acetate 86 Tacrolimus 79 dexamethasone 21-phosphate 73 Cyclosporine 68 Prednisone 67 isatuximab 66 auricularum 66 elotuzumab 62 belantamab mafodotin 58 Antilymphocyte Serum 56 Etoposide 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡